Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Giant Biogene Holding Co. Ltd. ( (HK:2367) ) has issued an announcement.
Giant Biogene Holding Co. Ltd. has scheduled a board meeting for 19 March 2026 to review and approve the group’s audited financial results for the year ended 31 December 2025. The board will also consider whether to recommend a final dividend and may handle other corporate matters, a step that will shape capital allocation decisions and provide investors with visibility on the company’s recent performance.
The announcement confirms the current composition of the company’s board, listing both executive and independent non-executive directors, underlining its existing governance framework ahead of the results review. Shareholders and market participants are likely to focus on the outcome of this meeting for signals on profitability, dividend policy and the company’s strategic direction going into the next financial year.
The most recent analyst rating on (HK:2367) stock is a Buy with a HK$36.00 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.
More about Giant Biogene Holding Co. Ltd.
Giant Biogene Holding Co. Ltd. is an exempted company incorporated in the Cayman Islands and listed in Hong Kong. The group operates in the biogene and biotech-related sector, with its business managed through a board comprising executive and independent non-executive directors based in Xi’an, China, reflecting a mainland China operating focus with offshore listing structure.
Average Trading Volume: 5,831,726
Technical Sentiment Signal: Sell
Current Market Cap: HK$31.87B
For an in-depth examination of 2367 stock, go to TipRanks’ Overview page.